Nabriva Therapeutics has announced the results of a clinical trial on lefamulin, which showed positive in vitro activity against all M. pneumoniae tested isolates.
The study’s results demonstrated lefamulin’s exceptional in vitro activity against all M. pneumoniae tested isolates, which was unaffected by resistance to macrolides, a class of natural antibiotics widely used against M. pneumoniae.
“Mycoplasma pneumonia is a major cause of CABP, estimated to be responsible for up to 50 percent of cases in children. Clinicians are concerned with the increasing prevalence of clinically significant resistance to macrolides in M. pneumoniae, spreading from Asia and Europe to the United States,” said Ken B. Waites, MD, F(AAM), professor of pathology and director of the Diagnostic Mycoplasma Laboratory at the University of Alabama at Birmingham, in a press release.
“These data demonstrate potent in vitro activity of lefamulin against all strains of M. pneumoniae tested regardless of resistance phenotype. Further assessment of lefamulin for the treatment of respiratory infections caused by M. pneumoniae is warranted,” he said.
“Lefamulin has consistently demonstrated potent in vitro activity against the most common gram-positive, gram-negative, and atypical bacterial causes of CABP, including multi-drug resistant strains. The data reported at ASM add to the robust in vitro evidence supporting the potential of this promising agent in the treatment of CABP,” said Steve Gelone, PharmD, Nabriva’s chief development officer.
